- Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
Multiple Sclerosis Centre of Veneto Region of Italy, Department of Neuroscience, University Hospital of Padova, Padova, Italy
Mult Scler 15:1359-62. 2009
..We suggest that relapsing-remitting MS patients having had a recent relapse should be treated with natalizumab only after achieving complete clinical and radiological remission...
- Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report
Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Via Giustiniani 5, 35128, Padua, Italy
Neurol Sci 31:317-20. 2011
..Our findings indicate a relevant activity of natalizumab against cortical inflammation in RRMS...
- Cortical lesions and cognitive impairment in multiple sclerosis
Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Padua, Italy
Neurol Sci 31:S235-7. 2010
- Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study
Multiple Sclerosis Centre, First Neurology Clinic, University of Padova, Via Giustiniani 5, Padova 35128, Italy
J Neurol Neurosurg Psychiatry 83:49-54. 2012
..The cause of epilepsy in multiple sclerosis (MS) has not yet been elucidated. The relevance of cortical pathology (cortical lesions and thickness) in MS patients with and without epilepsy was evaluated in a longitudinal study...
- Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
The Multiple Sclerosis Centre of the Veneto Region, Department of Neurology, University Hospital of Padova, Padova, Italy
Mult Scler 18:418-24. 2012
..To measure the effects of disease-modifying drugs (DMDs) on the development of cortical lesions (CL) and cortical atrophy in patients with relapsing-remitting multiple sclerosis (RRMS)...
- The predictive value of gray matter atrophy in clinically isolated syndromes
Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy
Neurology 77:257-63. 2011
..Methodologic and clinical constraints may take account for literature discrepancies...
- Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis
The Multiple Sclerosis Centre of Veneto Region, Department of Neurology, University Hospital of Padova, Italy
Mult Scler 18:1760-7. 2012
..Since cortical pathology has been indicated to play a relevant role in the physical and cognitive disability of multiple sclerosis (MS) patients, this study aims to analyze the efficacy of natalizumab in slowing down its progression...
- Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population
Multiple Sclerosis Centre of Veneto Region First Neurology Clinic, Department of Neurosciences, University Hospital of Padua, Italy
AJNR Am J Neuroradiol 33:1507-11. 2012
..Thus, we planned a longitudinal study aimed at analyzing and comparing cortical pathology in pediatric and adult MS patients at clinical onset...
- Increased incidence of multiple sclerosis in the Veneto region, Italy
The Multiple Sclerosis Centre of the Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Italy
Mult Scler 19:601-4. 2013
..To what extent the progressive increase in the incidence of multiple sclerosis (MS) observed in the province of Padova over the period 1970-1999 was an expression of a real increased risk of developing MS remained unclear...
- Widespread cortical thinning characterizes patients with MS with mild cognitive impairment
Department of Neurosciences, University Hospital of Padova, Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, 35128 Padova, Italy
Neurology 74:321-8. 2010
..Although cognitive dysfunction affects a relevant portion of patients with multiple sclerosis (MS), its pathologic substrate has not been clarified and it does not seem entirely explained by white matter changes...
- Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
Multiple Sclerosis Centre of Padova, University Hospital, Padova, Italy
Mult Scler 18:1640-3. 2012
..Clinical and/or MRI signs suggestive of disease rebound were observed in three patients. Our data indicate that fingolimod does not exert clinical activity quickly enough to stop MS reactivation after a break from natalizumab...
- Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency
First Neurology Clinic, Department of Neuroscience, University of Padua, Padova, Italy
Neurology 77:844-50. 2011
..Thus, we studied CCSVI prevalence in primary progressive (PP) and secondary progressive (SP) MS, to clarify whether CCSVI characterizes the progressive forms of this disease...
- BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset
Multiple Sclerosis Centre, Department of Neurosciences DNS, University Hospital Medical School, Via Giustiniani 5, 3518, Padova, Italy
J Neuroinflammation 14:11. 2017
..The in vivo analysis of intrathecally produced B cell-related cytokines may help to clarify the mechanisms of B cell recruitment and immunoglobulin production within the central nervous system (CNS) in MS...
- Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification
Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Via De Toni 5, 16132, Genoa, Italy
J Neuroimmune Pharmacol 7:665-72. 2012
..In conclusion, testing JCV-DNA in urine is complementary to testing anti-JCV antibodies in identifying patients at risk of PML...